Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 29;13(3):694-698.
doi: 10.21037/tlcr-23-820. Epub 2024 Mar 20.

DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges

Rebecca Y Bellis  1 , Prasad S Adusumilli  1   2 , Alfredo Amador-Molina  1
Affiliations
Editorial

DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges

Rebecca Y Bellis et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Small cell lung cancer (SCLC); chimeric antigen receptor T-cell (CAR T-cell); delta-like ligand 3 (DLL3); immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-820/coif). P.S.A. declares research funding from ATARA Biotherapeutics; scientific advisory board member and consultant for ATARA Biotherapeutics, Bayer, BioArdis, Carisma Therapeutics, Imugene, ImmPactBio, Orion pharma, and Outpace Bio; Patents, royalties, and intellectual property on MSLN-targeted CAR and other T-cell therapies licensed to ATARA Biotherapeutics, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to MSLN-targeted CARs and T-cell therapies to ATARA Biotherapeutics and has associated financial interests. P.S.A. also serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2023 to August 2025. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25. 10.1126/scitranslmed.3008226 - DOI - PMC - PubMed
    1. Cherkassky L, Hou Z, Amador-Molina A, et al. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cancer Cell 2022;40:569-74. 10.1016/j.ccell.2022.04.006 - DOI - PMC - PubMed
    1. Restle D, Dux J, Li X, et al. Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma. J Immunother Cancer 2023;11:e006609. 10.1136/jitc-2022-006609 - DOI - PMC - PubMed
    1. Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol 2023;16:66. 10.1186/s13045-023-01464-y - DOI - PMC - PubMed
    1. Zhang H, Yang Y, Li X, et al. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother 2023;159:114248. 10.1016/j.biopha.2023.114248 - DOI - PubMed